STOCK TITAN

FibroBiologics (FBLG) CSO buys 30,000 shares in open-market trade

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

FibroBiologics, Inc. Chief Scientific Officer Hamid Khoja reported an open-market purchase of 30,000 shares of common stock at $0.3800 per share. Following this transaction, he directly owns 61,250 common shares.

Positive

  • None.

Negative

  • None.
Insider Khoja Hamid
Role Chief Scientific Officer
Bought 30,000 shs ($11K)
Type Security Shares Price Value
Purchase Common Stock 30,000 $0.38 $11K
Holdings After Transaction: Common Stock — 61,250 shares (Direct)
Footnotes (1)
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Khoja Hamid

(Last) (First) (Middle)
C/O FIBROBIOLOGICS, INC.
455 E. MEDICAL CENTER BLVD., SUITE 300

(Street)
HOUSTON, TX 77598

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/04/2026 P 30,000 A $0.38 61,250 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Hamid Khoja 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FibroBiologics (FBLG) insider Hamid Khoja buy?

Hamid Khoja bought 30,000 shares of FibroBiologics common stock. The transaction was an open-market purchase at a price of $0.3800 per share, increasing his directly held stake in the company’s common shares.

When did FibroBiologics (FBLG) CSO Hamid Khoja purchase shares?

Hamid Khoja’s reported purchase occurred on March 4, 2026. On that date, he executed an open-market transaction to acquire 30,000 shares of FibroBiologics common stock, as disclosed in the Form 4 insider trading report.

How many FibroBiologics (FBLG) shares does Hamid Khoja own after the trade?

After the reported transaction, Hamid Khoja directly owns 61,250 FibroBiologics common shares. This reflects his holdings following the open-market purchase of 30,000 additional shares disclosed in the Form 4 filing.

Was the FibroBiologics (FBLG) insider trade a buy or a sell?

The insider trade by Hamid Khoja was a buy. The Form 4 shows an open-market purchase of 30,000 FibroBiologics common shares, coded as a purchase transaction rather than a sale or other type of disposition.

At what price did FibroBiologics (FBLG) insider Hamid Khoja buy shares?

Hamid Khoja bought his 30,000 FibroBiologics common shares at $0.3800 per share. This per-share purchase price is reported in the Form 4 filing that details the open-market acquisition.